TP53 and breast cancer: A study by Pfister et al., 2018 that aimed to identify drivers of aneuploidy in breast tumors found that (i) p53 was mutated in most aneuploid tumors, (ii) p53 mutations co-associate with overexpression of several mitotic transcription factors, and that (iii) in these tumors, and across all breast cancer subtypes, the oncogenes E2F1, B-MYB, and FOXM1 drive the overexpression of a network of mitotic proteins that ultimately diminishes the fidelity of chromosome segregation [132].